{"entity":{"id":"nct06812260","kind":"trial","name":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","aka":[],"tldr":"A phase 2 trial of HLX10+chemo in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.","summary":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT06812260 by Shanghai Henlius Biotech, with 26 participants enrolled, started 2025-06-24 and due to reach its primary completion in 2026-10-22. Interventions recorded: HLX10+chemo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06812260","url":"https://clinicaltrials.gov/study/NCT06812260"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06812260","phase":"2","setting":"A Single-arm, Open-label, Phase II Study to Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","sponsor":"Shanghai Henlius Biotech","enrolled":26,"outcomes":[]},"route":"/trials/nct06812260/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}